2024
Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer
Kunst N, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Rabil M, Ghaffar U, Karnes R, Ma X, Gross C, Wang S, Leapman M. Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer. JAMA Network Open 2024, 7: e2440591. PMID: 39441595, DOI: 10.1001/jamanetworkopen.2024.40591.Peer-Reviewed Original ResearchConceptsProstate-specific antigenProstate-specific antigen levelPSMA-PETRecurrent prostate cancerBiochemical recurrenceProstate cancerLong-term outcomesProstate-specific membrane antigen positron emission tomographyEvaluation of biochemical recurrenceDetection of biochemical recurrenceLife yearsConventional imagingDefinitive local therapyPSMA PET imagingProstate cancer deathDetection of metastasesRetrospective cohort studyBase case analysisIncremental life-yearsPositron emission tomographyDecision-analytic modelLocal therapyConventional imaging strategiesDelayed treatmentDisease course
2021
A prospective phase 2/3 study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A sub-analysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging.
Durack J, Alva A, Preston M, Pouliot F, Saperstein L, Carroll P, Pienta K, Rowe S, Patnaik A, Probst S, Stambler N, Jensen J, Wong V, Siegel B, Morris M. A prospective phase 2/3 study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A sub-analysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging. Journal Of Clinical Oncology 2021, 39: e17003-e17003. DOI: 10.1200/jco.2021.39.15_suppl.e17003.Peer-Reviewed Original ResearchF-DCFPyL PET/CTProstate cancerF-DCFPyLPositron emission tomographyConventional imagingM1 diseaseBone scintigraphyStaging of PCaHigh-risk prostate cancerWhole-body bone scintigraphyM1 stage diseasePhase 2/3 studyCT detection rateMajority of patientsPET/CTLocoregional diseaseRadiologic evidenceStage diseaseLocal recurrenceMetastatic diseasePelvic LNSingle doseTNM stagingImaging reviewLesion countsA prospective phase II/III study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A subanalysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging.
Durack J, Alva A, Preston M, Pouliot F, Saperstein L, Carroll P, Pienta K, Rowe S, Patnaik A, Probst S, Stambler N, Jensen J, Wong V, Siegel B, Morris M. A prospective phase II/III study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A subanalysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging. Journal Of Clinical Oncology 2021, 39: 32-32. DOI: 10.1200/jco.2021.39.6_suppl.32.Peer-Reviewed Original ResearchF-DCFPyL PET/CTProstate cancerF-DCFPyLPositron emission tomographyConventional imagingM1 diseaseBone scintigraphyPhase II/III studyStaging of PCaHigh-risk prostate cancerWhole-body bone scintigraphyM1 stage diseaseCT detection rateMajority of patientsPET/CTLocoregional diseaseRadiologic evidenceIII studyStage diseaseLocal recurrenceMetastatic diseasePelvic LNSingle doseTNM stagingImaging review